Applied DNA Sciences Inc (APDN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Applied DNA Sciences Inc (APDN) has a cash flow conversion efficiency ratio of -0.403x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.82 Million) by net assets ($6.99 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Review Applied DNA Sciences Inc (APDN) financial flexibility to assess the company's free cash flow relative to its total liabilities.
Applied DNA Sciences Inc - Cash Flow Conversion Efficiency Trend (2001–2025)
This chart illustrates how Applied DNA Sciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Also see Applied DNA Sciences Inc stock valuation for the company's overall valuation and market capitalisation.
Applied DNA Sciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Applied DNA Sciences Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Oriental Trimex Limited
NSE:ORIENTALTL
|
0.008x |
|
Zephyr Minerals Ltd
V:ZFR
|
0.006x |
|
Metalex Ventures Ltd.
V:MTX
|
-0.095x |
|
Collplant Biotechnologies Ltd
NASDAQ:CLGN
|
-0.309x |
|
Prima Alloy Steel Universal
JK:PRAS
|
0.006x |
|
Boku Inc
LSE:BOKU
|
0.369x |
|
SILVER HAMMER MINING CORP
F:7BW0
|
-0.026x |
|
Kuniko Ltd
AU:KNI
|
-0.069x |
Annual Cash Flow Conversion Efficiency for Applied DNA Sciences Inc (2001–2025)
The table below shows the annual cash flow conversion efficiency of Applied DNA Sciences Inc from 2001 to 2025. View APDN share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-09-30 | $1.94 Million | $-12.24 Million | -6.305x | -312.39% |
| 2024-09-30 | $8.97 Million | $-13.71 Million | -1.529x | -19.81% |
| 2023-09-30 | $4.87 Million | $-6.22 Million | -1.276x | -83.51% |
| 2022-09-30 | $12.91 Million | $-8.98 Million | -0.695x | +42.28% |
| 2021-09-30 | $11.11 Million | $-13.39 Million | -1.205x | +38.27% |
| 2020-09-30 | $5.71 Million | $-11.14 Million | -1.952x | -124.13% |
| 2019-09-30 | $-848.50K | $-6.86 Million | 8.087x | +188.21% |
| 2018-09-30 | $754.50K | $-6.92 Million | -9.168x | -740.66% |
| 2017-09-30 | $6.86 Million | $-7.48 Million | -1.091x | -14.22% |
| 2016-09-30 | $10.37 Million | $-9.90 Million | -0.955x | -72.25% |
| 2015-09-30 | $12.57 Million | $-6.97 Million | -0.554x | -109.56% |
| 2014-09-30 | $-1.47 Million | $-8.51 Million | 5.797x | +440.00% |
| 2013-09-30 | $4.62 Million | $-7.87 Million | -1.705x | +67.42% |
| 2012-09-30 | $756.92K | $-3.96 Million | -5.233x | -238.46% |
| 2011-09-30 | $-995.38K | $-3.76 Million | 3.779x | +145.98% |
| 2010-09-30 | $-1.60 Million | $-2.46 Million | 1.536x | +8.72% |
| 2009-09-30 | $-1.75 Million | $-2.47 Million | 1.413x | +577.91% |
| 2008-09-30 | $-14.04 Million | $-2.93 Million | 0.208x | +10.59% |
| 2007-09-30 | $-11.94 Million | $-2.25 Million | 0.189x | -37.34% |
| 2006-09-30 | $-9.59 Million | $-2.88 Million | 0.301x | +121.74% |
| 2005-09-30 | $6.59 Million | $-9.12 Million | -1.384x | -312.27% |
| 2004-09-30 | $-4.71 Million | $-3.07 Million | 0.652x | -23.40% |
| 2003-09-30 | $-577.43K | $-491.51K | 0.851x | -92.86% |
| 2001-09-30 | $-828.00 | $-9.87K | 11.914x | -- |
About Applied DNA Sciences Inc
Applied DNA Sciences, Inc., a biotechnology company, develops and commercializes technologies to produce and detect deoxyribonucleic acid (DNA) in the Americas, Europe, Asia, and internationally. It operates through three segments: Therapeutic DNA Production Services; MDx Testing Services; and DNA Tagging and Security Products and Services. The Therapeutic DNA Production Services segment develops… Read more